Literature DB >> 23618401

The non-coding RNA llme23 drives the malignant property of human melanoma cells.

Chuan-Fang Wu1, Guang-Hong Tan, Cheng-Chuan Ma, Ling Li.   

Abstract

Several lines of evidence support the notion that increased RNA-binding ability of polypyrimidine tract-binding (PTB) protein-associated splicing factor (PSF) and aberrant expression of long non-coding RNAs (lncRNAs) are associated with mouse and human tumors. To identify the PSF-binding lncRNA involved in human oncogenesis, we screened a nuclear RNA repertoire of human melanoma cell line, YUSAC, through RNA-SELEX affinity chromatography. A previously unreported lncRNA, termed as Llme23, was found to bind immobilized PSF resin. The specific binding of Llme23 to both recombinant and native PSF protein was confirmed in vitro and in vivo. The expression of PSF-binding Llme23 is exclusively detected in human melanoma lines. Knocking down Llme23 remarkably suppressed the malignant property of YUSAC cells, accompanied by the repressed expression of proto-oncogene Rab23. These results may indicate that Llme23 can function as an oncogenic RNA and directly associate the PSF-binding lncRNA with human melanoma.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23618401     DOI: 10.1016/j.jgg.2013.03.001

Source DB:  PubMed          Journal:  J Genet Genomics        ISSN: 1673-8527            Impact factor:   4.275


  22 in total

Review 1.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

Review 2.  New insights in melanoma biomarkers: long-noncoding RNAs.

Authors:  Ricardo Moreno-Traspas; Igor Vujic; Martina Sanlorenzo; Susana Ortiz-Urda
Journal:  Melanoma Manag       Date:  2016-08-16

3.  The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.

Authors:  Cibele Cardoso; Rodolfo B Serafim; Akinori Kawakami; Cristiano Gonçalves Pereira; Jason Roszik; Valeria Valente; Vinicius L Vazquez; David E Fisher; Enilza M Espreafico
Journal:  Pigment Cell Melanoma Res       Date:  2018-12-16       Impact factor: 4.693

Review 4.  Rab23 activities and human cancer-emerging connections and mechanisms.

Authors:  Yanan Chen; Fanny Ng; Bor Luen Tang
Journal:  Tumour Biol       Date:  2016-07-23

Review 5.  Long non-coding RNAs in melanoma.

Authors:  Xin Yu; Heyi Zheng; Gary Tse; Matthew Tv Chan; William Kk Wu
Journal:  Cell Prolif       Date:  2018-03-26       Impact factor: 6.831

Review 6.  Melanoma epigenetics: novel mechanisms, markers, and medicines.

Authors:  Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Lab Invest       Date:  2014-06-30       Impact factor: 5.662

7.  The lncRNA SLNCR1 Mediates Melanoma Invasion through a Conserved SRA1-like Region.

Authors:  Karyn Schmidt; Cailin E Joyce; Frank Buquicchio; Adam Brown; Justin Ritz; Robert J Distel; Charles H Yoon; Carl D Novina
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

8.  The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching.

Authors:  Laurent Lessard; Michelle Liu; Diego M Marzese; Hongwei Wang; Kelly Chong; Neal Kawas; Nicholas C Donovan; Eiji Kiyohara; Sandy Hsu; Nellie Nelson; Sivan Izraely; Orit Sagi-Assif; Isaac P Witz; Xiao-Jun Ma; Yuling Luo; Dave S B Hoon
Journal:  J Invest Dermatol       Date:  2015-05-27       Impact factor: 8.551

Review 9.  Revealing protein-lncRNA interaction.

Authors:  Fabrizio Ferrè; Alessio Colantoni; Manuela Helmer-Citterich
Journal:  Brief Bioinform       Date:  2015-06-02       Impact factor: 11.622

Review 10.  Epigenetic regulation in human melanoma: past and future.

Authors:  Debina Sarkar; Euphemia Y Leung; Bruce C Baguley; Graeme J Finlay; Marjan E Askarian-Amiri
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.